Chemotherapy - Pharmacy Technician Pulse

Pharmacist Follow-up Improves Patient Quality of Life After Emetogenic Chemotherapy

Drug Topics

NOVEMBER 8, 2022

Follow-ups from pharmacists show a significant increase in outpatient antiemetic drugs prescribed and quality of life in patients experiencing chemotherapy-induced nausea and vomiting.

Chemotherapy

FDA Approves Nivolumab Plus Chemotherapy for Unresectable or Metastatic Urothelial Carcinoma

Drug Topics

MARCH 8, 2024

A clinical trial showed that nivolumab plus chemotherapy significantly improved overall survival and progression-free survival compared with a chemotherapy combination alone.

Chemotherapy

Chemotherapy FDA

Ocular Adverse Events Linked to Chemotherapies Paclitaxel and Docetaxel

Drug Topics

SEPTEMBER 6, 2022

Patients who received the chemotherapies paclitaxel and docetaxel were at an increased risk of adverse events of the eye.

Chemotherapy

STAT+: Drug may make chemotherapies less effective in cancer patients with obesity — but many doctors are in the dark

STAT

OCTOBER 28, 2024

This means chemotherapies may be less effective when interacting with the medicine, but some clinicians, and their patients, are unaware of that possibility. A drug used to combat fungal infections in cancer patients comes with a big caveat — research shows the medicine can last twice as long as in people with obesity.

Chemotherapy

Chemotherapy Labelling

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

This new guidance will clearly impact the clinical research field, but how?

FDA

High BMI in Breast Cancer Patients Linked With Increased Cardiotoxicity During Chemotherapy

Drug Topics

AUGUST 9, 2023

A recent study being presented at the American College of Cardiology Latin America 2023 conference found the prevalence of cardiotoxicity among patients with breast cancer undergoing chemotherapy was 11.94%.

Chemotherapy

Combining Keytruda And Chemo May Improve Survival in Advanced Endometrial Cancer

Drug Topics

MAY 8, 2023

Patients with advanced or recurrent endometrial cancer treated with Keytruda plus chemotherapy had improved progression-free survival compared with chemotherapy alone.

Chemotherapy

Women Treated for Breast Cancer Experience Accelerated Biological Aging

Drug Topics

JULY 25, 2023

Radiation therapy was associated with the largest increase, compared to chemotherapy or endocrine therapies.

Chemotherapy

Personalized Survivorship Plans for Colon Cancer Patients Receiving Adjuvant Chemotherapy

Drug Topics

OCTOBER 23, 2023

Survivorship care for patients with colon cancer should include comprehensive coordination between oncologists, specialists, and primary care providers and include psychological and economic factors in addition to standard health recommendations.

Chemotherapy

FDA Approves Denosumab-Bmwo as Biosimilar to Prolia, Xgeva

Drug Topics

MARCH 4, 2025

Denosumab-Bmwo is approved for all indications of the respective reference products, including osteoporosis and high-risk of fracture due to chemotherapy.

Chemotherapy

Chemotherapy FDA

Researchers Identify Chemotherapy Resistance Biomarkers in Triple-Negative Breast Cancer

Pharmacy Times

SEPTEMBER 2, 2022

DNA and RNA sequencing could provide insight about resistance to chemotherapy in patients suffering from triple-negative breast cancer.

Chemotherapy

Study: Chemotherapy to Treat Breast Cancer Increases Risk of Lung Cancer

Pharmacy Times

APRIL 19, 2024

Individuals treated with chemotherapy following a breast cancer diagnosis were more at risk of developing second primary lung cancer.

Chemotherapy

Drug Shortages in Community Oncology: Ensuring Access to Chemotherapy

Pharmacy Times

JUNE 17, 2024

Persistent chemotherapy drug shortages challenge oncology providers. American Oncology Network employs a drug shortage committee for organized shortage management that involves pharmacists and interdisciplinary stakeholders.

Chemotherapy

Cisplatin-Based Chemotherapy Linked to Hearing Loss in Cancer Survivors

Pharmacy Times

JULY 10, 2024

Extended treatment with high doses of cisplatin-based chemotherapy is associated with severe and progressive hearing loss.

Chemotherapy

NCCN Calls on Federal Agencies, Payers, to Take Action on Chemotherapy Drug Shortages

Drug Topics

JUNE 8, 2023

Carboplatin and cisplatin are currently in short supply.

Chemotherapy

FDA Accepts sBLA for Dostarlimab With Chemotherapy to Treat Endometrial Cancer

Pharmacy Times

APRIL 25, 2024

Dostarlimab plus chemotherapy is the only immuno-oncology-based therapy that showed statistically significant and clinically meaningful survival benefit in the overall patient population.

Chemotherapy

Chemotherapy FDA

The DETECT V Trial: Exploring Chemotherapy-Free Treatment for HER2+/HR+ Metastatic Breast Cancer

Pharmacy Times

SEPTEMBER 16, 2024

Data from the second interim analysis of the DETECT V trial, presented at ESMO Congress 2024, suggest that a chemotherapy-free regimen combining dual HER2-targeted therapy with endocrine therapy, particularly with the addition of ribociclib, may be an effective treatment for patients.

Chemotherapy

Nivolumab-Chemotherapy Combination Lengthens Survival, Causes Manageable Adverse Effects in Stage III or IV Classic Hodgkin Lymphoma

Pharmacy Times

OCTOBER 17, 2024

Compared with brentuximab vedotin and chemotherapy, nivolumab and chemotherapy had longer progression-free survival and a better safety profile.

Chemotherapy

Using CGM to Evaluate Hyperglycemia in Patients with Early Stage Breast Cancer

Drug Topics

JUNE 11, 2024

In a study presented at ASCO 2024, investigators found that all 20 included patients with early stage breast cancer receiving chemotherapy developed hyperglycemia.

Chemotherapy

Novel device opens blood-brain barrier to deliver chemotherapy

European Pharmaceutical Review

MAY 3, 2023

The blood-brain barrier (BBB) in glioblastoma patients was opened temporarily using a novel, skull-implantable ultrasound device to deliver chemotherapy to the brain in a first in-human trial. Two chemotherapy drugs , paclitaxel and carboplatin were injected intravenously during the four-minute procedure.

Chemotherapy

As Chemotherapy Drug Shortage Continues, Unimaginable Decisions and Lacking Accountability Reign

Pharmacy Times

JULY 24, 2023

Treatment providers have been forced to adapt and make potentially life-altering decisions for patients due to persistent chemotherapy drug shortages, all while solutions from the FDA and drug manufacturers remain scant.

Chemotherapy

Chemotherapy FDA

First Immunotherapy Combo Treatment Approved for Biliary Tract Cancers

Drug Topics

SEPTEMBER 14, 2022

FDA approves durvalumab to treat biliary tract cancer in combination with chemotherapy.

Chemotherapy

Chemotherapy FDA

New chemotherapy treatment could benefit multiple cancer types

European Pharmaceutical Review

FEBRUARY 15, 2024

A clinical trial in malignant pleural mesothelioma (MPM) has demonstrated the first successful combination of chemotherapy with a drug targeting cancer’s metabolism developed for the asbestos-induced disease in two decades. The anti-cancer treatment combines the new drug ADI-PEG20 and traditional chemotherapy.

Chemotherapy

FDA approves J&J’s Rybrevant with chemotherapy for NSCLC treatment

Pharmafile

MARCH 4, 2024

The drug has been approved in combination with chemotherapy (carboplatin-pemetrexed) for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 […] The post FDA approves J&J’s Rybrevant with chemotherapy for NSCLC treatment appeared (..)

Chemotherapy

Chemotherapy FDA

FDA Approves Tislelizumab-jsgr for Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy

Pharmacy Times

MARCH 14, 2024

Results from the phase 3 RATIONALE 302 trial showed tislelizumab-jsgr prolonged survival compared to chemotherapy in patients who received prior systemic treatment.

Chemotherapy

Chemotherapy FDA

Evaluating Changes in Systemic Anticancer Therapy Use Between 2015 and 2019

Drug Topics

NOVEMBER 11, 2022

While the use of chemotherapy at end of life is decreasing, the use of immunotherapy is increasing.

Chemotherapy

Non-chemotherapy lymphoma treatment may provide durable remission

European Pharmaceutical Review

JUNE 19, 2024

A non-chemotherapy multi-drug therapy enabled complete remission in 38 percent of evaluable patients with aggressive B-cell lymphoma, a Phase Ib/II clinical trial shows. The post Non-chemotherapy lymphoma treatment may provide durable remission appeared first on European Pharmaceutical Review.

Chemotherapy

Endometrial Cancer Treatment Linked to Long-Term Bowel Dysfunction in Older Women

Drug Topics

OCTOBER 25, 2023

Older women who had a hysterectomy without chemotherapy and/or radiation had less chance of gastrointestinal issues than women who had those treatments.

Chemotherapy

FDA Approves Sacituzumab Govitecan in Pretreated Metastatic Breast Cancer

Drug Topics

FEBRUARY 3, 2023

Sacituzumab govitecan significantly improved overall survival over the comparator chemotherapy in patients with hormone receptor–positive, human epidermal growth factor receptor 2–negative breast cancer who had received prior treatment.

Chemotherapy

Chemotherapy FDA

STAT+: Merck, Daiichi Sankyo to partner on targeted chemotherapy drugs in deal worth up to $22 billion

STAT

OCTOBER 19, 2023

MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around targeted chemotherapy treatments. The deal includes a $4 billion upfront payment and an additional $1.5 billion over the next two years.

Chemotherapy

STAT+: Hair loss is one of the most hated chemotherapy side effects. A new biotech hopes to prevent it

STAT

JANUARY 17, 2024

The chemotherapy Christine Ko was prescribed for her breast cancer is pretty much a guarantee for losing your hair. The company is currently developing an antibody that might reliably protect the head’s hair follicles from chemotherapy damage — if it works. But, to her, it wasn’t much of an option.

Chemotherapy

Durvalumab With Chemotherapy Shows Long-Term Overall Survival at 3 Years

Pharmacy Times

APRIL 18, 2024

The results were the longest survival follow-up ever reported for a phase 3 trial for biliary tract cancer.

Chemotherapy

STAT+: Jazz Pharmaceuticals to acquire Chimerix and its experimental brain cancer drug

STAT

MARCH 5, 2025

It responds poorly to chemotherapy and is usually driven by a mutation that can’t be drugged with traditional approaches. The tumor, known as diffuse midline glioma, or DMG (and sometimes as DIPG depending on where it’s found), has flummoxed researchers for decades. Median survival is generally cited as less than a year.

Chemotherapy

FDA Approves Pembrolizumab Plus Pemetrexed and Platinum Chemotherapy for Malignant Pleural Mesothelioma

Pharmacy Times

SEPTEMBER 18, 2024

The approval is based on positive results from the phase 2/3 IND.227/KEYNOTE-483 227/KEYNOTE-483 trial.

Chemotherapy

Chemotherapy FDA

Blinatumomab Plus Chemotherapy Improves DFS in Pediatric Patients With SR B-ALL

Pharmacy Times

DECEMBER 7, 2024

In newly diagnosed average and high standard risk B-cell acute lymphoblastic leukemia (B-ALL), blinatumomab improved disease-free survival (DFS) by approximately 97.5% and 94.1%, respectively.

Chemotherapy

Tislelizumab Demonstrates Superior Overall Survival Compared With Chemotherapy

Pharmacy Times

APRIL 24, 2023

Efficacy and safety data for BeiGene’s therapy shows positive results for individuals with advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

Chemotherapy

FDA Approves Osimertinib With Chemotherapy for EGFRm NSCLC

Pharmacy Times

FEBRUARY 19, 2024

Osimertinib was previously approved as a monotherapy, the first-in-line global standard of care, for non–small cell lung cancer indications.

Chemotherapy

Chemotherapy FDA

Enfortumab Vedotin Plus Pembrolizumab Outperforms Chemotherapy in Advanced Urothelial Carcinoma

Pharmacy Times

FEBRUARY 13, 2025

The combination greatly improved progression-free survival and overall survival.

Chemotherapy

Researchers Find “Digital Twin” Model Accurately Predicts Treatment Responses for Different Chemotherapy Drugs

Pharmacy Times

OCTOBER 30, 2024

This model, which uses technology that discovers black holes, pulls from real data to evaluate cancer treatments, optimizing treatment choices for patients with different cancers.

Chemotherapy

FDA Approves Pembrolizumab With Chemotherapy to Treat Adult Patients With Endometrial Carcinoma

Pharmacy Times

JUNE 18, 2024

The indication is for adult patients with primary advanced or recurrent endometrial carcinoma and is the third indication that pembrolizumab has received for this disease state.

Chemotherapy

Chemotherapy FDA

Topical Minoxidil Improves Hair Growth in 87% of Pediatric Patients With Chemotherapy-Induced Alopecia

Pharmacy Times

MARCH 18, 2024

The FDA-approved topical and oral agent is currently indicated for adult patients with patterned alopecia.

Chemotherapy

Chemotherapy FDA

High-Dose Vitamin C Improves Outcomes for Late-Stage Pancreatic Cancer

Pharmacy Times

DECEMBER 3, 2024

High-dose vitamin C, when combined with chemotherapy, has shown the potential to double the survival rate of patients with late-stage metastatic pancreatic cancer.

Chemotherapy

FDA Expands Approval of Dostarlimab-Gxly Plus Chemotherapy to All Adults With Primary, Recurrent Endometrial Cancer

Pharmacy Times

AUGUST 1, 2024

The RUBY trial will continue and analyze the overall population survival after treatment with the drug combination.

Chemotherapy

Chemotherapy FDA

FDA Approves Pembrolizumab Plus Chemotherapy to Treat Metastatic HER2-Negative Gastric, Gastroesophageal Junction Adenocarcinoma

Pharmacy Times

NOVEMBER 17, 2023

The approval makes pembrolizumab the first-line treatment for individuals with this cancer.

Chemotherapy

Chemotherapy FDA

Pharmacist Follow-up Improves Patient Quality of Life After Emetogenic Chemotherapy

FDA Approves Nivolumab Plus Chemotherapy for Unresectable or Metastatic Urothelial Carcinoma

Trending Sources

Ocular Adverse Events Linked to Chemotherapies Paclitaxel and Docetaxel

STAT+: Drug may make chemotherapies less effective in cancer patients with obesity — but many doctors are in the dark

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

High BMI in Breast Cancer Patients Linked With Increased Cardiotoxicity During Chemotherapy

Combining Keytruda And Chemo May Improve Survival in Advanced Endometrial Cancer

Women Treated for Breast Cancer Experience Accelerated Biological Aging

Personalized Survivorship Plans for Colon Cancer Patients Receiving Adjuvant Chemotherapy

FDA Approves Denosumab-Bmwo as Biosimilar to Prolia, Xgeva

Researchers Identify Chemotherapy Resistance Biomarkers in Triple-Negative Breast Cancer

Study: Chemotherapy to Treat Breast Cancer Increases Risk of Lung Cancer

Drug Shortages in Community Oncology: Ensuring Access to Chemotherapy

Cisplatin-Based Chemotherapy Linked to Hearing Loss in Cancer Survivors

NCCN Calls on Federal Agencies, Payers, to Take Action on Chemotherapy Drug Shortages

FDA Accepts sBLA for Dostarlimab With Chemotherapy to Treat Endometrial Cancer

The DETECT V Trial: Exploring Chemotherapy-Free Treatment for HER2+/HR+ Metastatic Breast Cancer

Nivolumab-Chemotherapy Combination Lengthens Survival, Causes Manageable Adverse Effects in Stage III or IV Classic Hodgkin Lymphoma

Using CGM to Evaluate Hyperglycemia in Patients with Early Stage Breast Cancer

Novel device opens blood-brain barrier to deliver chemotherapy

As Chemotherapy Drug Shortage Continues, Unimaginable Decisions and Lacking Accountability Reign

First Immunotherapy Combo Treatment Approved for Biliary Tract Cancers

New chemotherapy treatment could benefit multiple cancer types

FDA approves J&J’s Rybrevant with chemotherapy for NSCLC treatment

FDA Approves Tislelizumab-jsgr for Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy

Evaluating Changes in Systemic Anticancer Therapy Use Between 2015 and 2019

Non-chemotherapy lymphoma treatment may provide durable remission

Endometrial Cancer Treatment Linked to Long-Term Bowel Dysfunction in Older Women

FDA Approves Sacituzumab Govitecan in Pretreated Metastatic Breast Cancer

STAT+: Merck, Daiichi Sankyo to partner on targeted chemotherapy drugs in deal worth up to $22 billion

STAT+: Hair loss is one of the most hated chemotherapy side effects. A new biotech hopes to prevent it

Durvalumab With Chemotherapy Shows Long-Term Overall Survival at 3 Years

STAT+: Jazz Pharmaceuticals to acquire Chimerix and its experimental brain cancer drug

FDA Approves Pembrolizumab Plus Pemetrexed and Platinum Chemotherapy for Malignant Pleural Mesothelioma

Blinatumomab Plus Chemotherapy Improves DFS in Pediatric Patients With SR B-ALL

Tislelizumab Demonstrates Superior Overall Survival Compared With Chemotherapy

FDA Approves Osimertinib With Chemotherapy for EGFRm NSCLC

Enfortumab Vedotin Plus Pembrolizumab Outperforms Chemotherapy in Advanced Urothelial Carcinoma

Researchers Find “Digital Twin” Model Accurately Predicts Treatment Responses for Different Chemotherapy Drugs

FDA Approves Pembrolizumab With Chemotherapy to Treat Adult Patients With Endometrial Carcinoma

Topical Minoxidil Improves Hair Growth in 87% of Pediatric Patients With Chemotherapy-Induced Alopecia

High-Dose Vitamin C Improves Outcomes for Late-Stage Pancreatic Cancer

FDA Expands Approval of Dostarlimab-Gxly Plus Chemotherapy to All Adults With Primary, Recurrent Endometrial Cancer

FDA Approves Pembrolizumab Plus Chemotherapy to Treat Metastatic HER2-Negative Gastric, Gastroesophageal Junction Adenocarcinoma

Stay Connected